Get the Stockscreener App
0.9403
7.81%
-0.0797
Pre-market:
.99
0.0497
+5.29%
Inflarx N V stock is traded at $0.9403, with a volume of 384.93K.
It is down -7.81% in the last 24 hours and up +0.72% over the past month.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$1.02
Open:
$1
24h Volume:
384.93K
Relative Volume:
0.83
Market Cap:
$67.98M
Revenue:
$208.60K
Net Income/Loss:
$-58.59M
P/E Ratio:
-1.0261
EPS:
-0.9164
Net Cash Flow:
$-47.11M
1W Performance:
+6.85%
1M Performance:
+0.72%
6M Performance:
-27.11%
1Y Performance:
-29.30%
1-Day Range:
$0.9401
$1.07
1-Week Range:
$0.81
$1.07
52-Week Range:
$0.7113
$1.94
Inflarx N V Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
0.9403 | 67.98M | 208.60K | -58.59M | -47.11M | -0.9164 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-02-25 | Resumed | H.C. Wainwright | Buy |
| May-29-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-06-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-20 | Initiated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Apr-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-05-19 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-05-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-05-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Jun-05-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| Dec-10-18 | Initiated | Credit Suisse | Outperform |
| Jul-13-18 | Initiated | BMO Capital Markets | Outperform |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-28-18 | Initiated | SunTrust | Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Inflarx N V Stock (IFRX) Latest News
Treasury Yields: Can InflaRx NV sustain earnings growth2026 Earnings Surprises & Daily Stock Momentum Reports - baoquankhu1.vn
Can InflaRx's Vilobelimab Stage A Revival In Pyoderma Gangrenosum? - RTTNews
HC Wainwright Forecasts InflaRx's Q3 Earnings (NASDAQ:IFRX) - MarketBeat
Analyst Upgrade: Is InflaRx NV a top pick in the sector2026 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
Aug Shorts: Can InflaRx NV sustain earnings growthMarket Movement Recap & Community Trade Idea Sharing - baoquankhu1.vn
Bear Alert: Is InflaRx NV a top pick in the sector2026 Gainers & Daily Momentum Trading Reports - baoquankhu1.vn
InflaRx NV (IFRX) reports Q4 loss, lags revenue estimates - MSN
Raymond James raises Inflarx stock price target on drug trial data - Investing.com India
InflaRx Survival Hopes Rest On Izicopan - Citeline News & Insights
InflaRx (NASDAQ:IFRX) Given New $14.00 Price Target at Guggenheim - MarketBeat
Guggenheim cuts Inflarx stock price target on model update to $14 - Investing.com Canada
Guggenheim cuts Inflarx stock price target on model update to $14 By Investing.com - Investing.com Australia
Q1 Earnings Forecast for InflaRx Issued By HC Wainwright - MarketBeat
InflaRx (IFRX) posts 2025 loss, relies on cash runway and grants - Stock Titan
InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
InflaRx NV reports results for the quarter ended December 31Earnings Summary - TradingView
IFRX: Izicopan's promising Phase 2a data drives strategic focus and extends cash runway to mid-2027 - TradingView
InflaRx (NASDAQ:IFRX) Issues Earnings Results, Meets Expectations - MarketBeat
InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
InflaRx Shifts Strategy to Izicopan as 2025 Results Extend Cash Runway to 2027 - TipRanks
Inflarx reports full year 2025 results and highlights key achievements and expected milestones - marketscreener.com
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones - The Manila Times
InflaRx (IFRX) narrows 2025 loss, shifts focus to izicopan growth - Stock Titan
IFRX: Izicopan advances as the lead asset with strong Phase 2a data, cost cuts, and extended cash runway - TradingView
InflaRx N.V. (IFRX) Posts Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
InflaRx to present Phase 3 pyoderma gangrenosum data at AAD By Investing.com - Investing.com South Africa
InflaRx FY 2025 earnings preview - MSN
Aug Opening: Is InflaRx NV forming bullish engulfing patterns2026 PreEarnings & Precise Buy Zone Tips - baoquankhu1.vn
Aug Levels: Can InflaRx NV outperform under higher oil prices2026 Growth vs Value & Verified Swing Trading Watchlist - baoquankhu1.vn
InflaRx (IFRX) director Mark Kubler reports 960,015 shares and multiple options - Stock Titan
InflaRx (IFRX) director lists options and 10,000 Ordinary Shares - Stock Titan
InflaRx (IFRX) director Brudnick reports shares and multiple stock option grants - Stock Titan
InflaRx (IFRX) director details vested and future stock options - Stock Titan
InflaRx (IFRX) CSO discloses 1.76M shares and multiple option grants - Stock Titan
InflaRx (IFRX) officer discloses vested and performance stock options - Stock Titan
InflaRx (IFRX) director discloses sizeable share and option stakes - Stock Titan
InflaRx (IFRX) CEO reports 1,068,908 shares plus option grants - Stock Titan
InflaRx (IFRX) CFO details extensive stock option and share holdings - Stock Titan
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting - The Manila Times
InflaRx N.V. to Present Phase 3 Study Data on Vilobelimab for Pyoderma Gangrenosum at AAD 2026 Annual Meeting - Quiver Quantitative
Vilobelimab Phase 3 data earns late-breaker slot at AAD 2026 meeting - Stock Titan
InflaRx NV expected to post a loss of 15 cents a shareEarnings Preview - TradingView
InflaRx (IFRX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
InflaRx receives Nasdaq notification - MSN
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - Sahm
InflaRx receives Nasdaq notice over minimum bid price rule By Investing.com - Investing.com South Africa
InflaRx Receives Nasdaq Deficiency Notice Over Minimum Bid Price - National Today
InflaRx (IFRX) hit with Nasdaq minimum $1 bid-price warning and cure window - Stock Titan
InflaRx receives Nasdaq notice over minimum bid price rule - Investing.com
InflaRx to Report Full Year 2025 Results on March 19, 2026 - Sahm
InflaRx (IFRX) to Release Earnings on Thursday - MarketBeat
Inflarx N V Stock (IFRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):